Latest Breaking News On - Closure glaucoma - Page 1 : vimarsana.com

World Glaucoma Day 2024: Expert Debunks Glaucoma Myths And Shares Tips To Manage The Eye Disease

World Glaucoma Day is observed annually on March 12th. This day is dedicated to raising awareness about glaucoma, a group of eye conditions that can lead to optic nerve damage and vision loss. Glaucoma often develops gradually and is characterized by increased pressure in the eyes, which can damage the optic nerve. Read on to know symptoms, myths and misconceptions, and preventive measures. , Health News, Times Now

Glaucoma: Lack Of Timely Treatment Can Lead To Blindness - Check Risks And Symptoms

Glaucoma Awareness Month: Several factors increase the risk of developing glaucoma. Regular eye check-ups, especially for those with risk factors, are paramount, as is awareness because often, it goes undetected in its initial stages. 

Glaucoma Treatment Market Set to Surge at 4.3% CAGR, to Reach USD 9.1 billion by 2031 | Transparency Market Research, Inc.

Glaucoma Treatment Market Set to Surge at 4.3% CAGR, to

Increasing research and innovation in various treatment options will drive demand for glaucoma treatment..

Glaucoma –the killer cause of blindness – The Sun Nigeria

Sun Pharma Announces Drizalma Sprinkle™ (duloxetine delayed-release capsules) is Now Covered by Most Medicare Part D Plans

Share this article Share this article PRINCETON, N.J., March 9, 2021 /PRNewswire/ Sun Pharmaceutical Industries, Inc. (Sun Pharma), a wholly owned subsidiary of Mumbai-based Sun Pharmaceutical Industries Limited, today announced that the top 10 Medicare Part D plans, which include 91% of eligible U.S. lives, now cover Drizalma Sprinkle™. Drizalma Sprinkle™ is one of three sprinkle formulation products in Sun Pharma s long-term care (LTC) portfolio, which are prescribed inside and outside of LTC facilities for the 40% of American adults who cannot or will not swallow solid medication forms.  Drizalma Sprinkle™ is the first and only U.S. Food and Drug Administration (FDA) approved sprinkle formulation of delayed-release duloxetine capsules and is indicated to treat major depressive disorder (MDD), generalized anxiety disorder (GAD) in adults and pediatric patients aged 7-17, diabetic peripheral neuropathy pain (DPNP), and chronic musculoskeletal pain in adults. Sun Phar

Global Antiglaucoma Drugs Market Report 2020: COVID-19 Impact and Recovery - Forecast to 2023, 2025 & 2030

Share this article Share this article ResearchAndMarkets.com s offering. This report describes and evaluates the global antiglaucoma drugs market. It covers 2015 to 2019, termed the historic period, and 2019 to 2023 termed the forecast period, along with further forecasts for the periods 2023-2025 and 2025-2030. The global antiglaucoma drugs market reached a value of nearly $6,591.8 million in 2019, having increased at a compound annual growth rate (CAGR) of 4.2% since 2015. The market is expected to decline from $6,591.8 million in 2019 to $5,191.2 million in 2020 at a rate of -21.2%. The decline is mainly due to lockdown and social distancing norms imposed by various countries and economic slowdown across countries owing to the COVID-19 outbreak and the measures to contain it. The market is then expected to recover and grow at a CAGR of 5.0% to $6,659.2 million in 2021 and reach $ 7,345.6 million in 2023 at a CAGR of 2.7%. The market is expected to reach $8,089.0 million in